Dracenax is indicated only to postmenopausal HR+ breast cancer patients.

Dracenax is indicated also in advanced HR+ breast cancer patients.

Dracenax has demonstrated efficacy in patients with hormone receptor negative breast cancer.

Dose adjustment is recommended for elderly patients taking Dracenax.

How is Dracenax taken in advanced breast cancer?

The following are contraindications of Dracenax, except for one.

These are the most frequently reported adverse events in the clinical trials, except for one.

Isolated cases of overdosage with Letrozole have been reported

Dracenax inhibits the aromatase enzyme by competitively binding to the hem of the aromatase cytochrome P450, resulting in the rapid reduction of estrogen biosynthesis in all tissues where present.

BIG 1-98 was a multicenter, double-blind study in which over 8,000 postmenopausal women with hormone receptor-positive early breast cancer were randomized to one of the following treatments: A. tamoxifen for 5 years; B. Letrozole for 5 years; C. tamoxifen for 2 years followed by Letrozole for 3 years; D. Letrozole for 2 years followed by tamoxifen for 5 years.

What is the primary endpoint of BIG-198?

The following are the secondary endpoints of BIG-198, except for one.

In a multicenter, double-blind, randomized, placebo-controlled study (MA-17), over 5,100 postmenopausal women with receptor-positive or unknown primary breast cancer who had completed adjuvant treatment with Tamoxifen (4.5 to 6 years) were randomized to either letrozole or tamoxifen for 5 years.

It is defined as the interval between randomization and the earliest occurrence of loco-regional recurrence, distant metastasis, or contralateral breast cancer.

What is the median follow up in the final analysis of MA17?

Use of Letrozole in in men with breast cancer has been studied.

Letrozole is rapidly and completely absorbed from the gastrointestinal tract.

What is the terminal elimination half-life in plasma of Letrozole?

Where is Dracenax manufactured?